Clinical Trials Logo

Filter by:
NCT ID: NCT02810028 Completed - Muscle Diseases Clinical Trials

Acceptance and Commitment Therapy for Muscle Disease

ACTMuS
Start date: July 2016
Phase: N/A
Study type: Interventional

In adults, muscle diseases are usually chronic long-term conditions that do not have a definitive cure. Supportive care has been shown to reduce complications from muscle disease and improved survival in some cases. However, there has been limited research to evaluate interventions that may improve quality of life (QoL) with this patient group. The QoL of those with MD is not just affected by the severity of their MD but also a variety of psychological variables. Based upon the knowledge of these psychological variables the investigators feel that a particular type of psychological intervention known as "acceptance and commitment therapy" (ACT) could potentially improve QoL in those with MD. The investigators therefore propose to test whether ACT does in fact improve QoL in those with MD by randomising 154 patients to receive either standard medical care plus a guided self-help ACT programme, or standard medical care only.

NCT ID: NCT02809547 Completed - Clinical trials for Rheumatoid Arthritis

RADAR1- Trial of a New Blood Sample Method (Remote Arthritis Disease Activity MonitoR)

RADAR
Start date: November 2016
Phase: N/A
Study type: Interventional

It is important that patients who suffer from Rheumatoid Arthritis (RA) have their disease monitored at an early stage, as well as when it is established. Presently, if a patient is to be assessed by means of disease activity scores and blood tests, they must attend a hospital appointment, which can be difficult for patients who live far from the clinic. It would be beneficial to be able to monitor and reliably define and report a disease 'flare' at home. Quite often, by the time the patient attends for an appointment, flare ups have subsided. This study will evaluate the possibility for patients to take their own blood samples in the comfort of their own home, by transferring finger prick blood droplets to a dried blood spot sample (DBSS) card. Patients would then send the cards to the laboratory to test for clinically relevant protein markers. The feasibility of 'remote' monitoring of the patient's disease will be explored.

NCT ID: NCT02809053 Completed - Clinical trials for Lymphoma, Follicular

A Randomized, Double-blind, Multi-center, Multi-national Trial to Evaluate the Efficacy, Safety, and Immunogenicity of SAIT101 Versus Rituximab as a First-line Immunotherapy Treatment in Patients With Low Tumor Burden Follicular Lymphoma

RAMO-2
Start date: January 18, 2017
Phase: Phase 3
Study type: Interventional

This is a Randomized, Double-blind, Multi-center, Multi-national Trial to Evaluate the statistical equivalence of efficacy, safety and immunogenicity of SAIT101 Versus Rituximab as a First-line Immunotherapy Treatment in asymptomatic patients with Low Tumor Burden Follicular Lymphoma.

NCT ID: NCT02808975 Completed - Clinical trials for Hidradenitis Suppurativa (HS)

Safety and Efficacy of Adalimumab (Humira) for Hidradenitis Suppurativa (HS) Peri-Surgically

SHARPS
Start date: July 18, 2016
Phase: Phase 4
Study type: Interventional

The objective of this study was to assess the safety and efficacy of adalimumab prior to surgery in participants with moderate to severe Hidradenitis Suppurativa (HS) who were surgical candidates.

NCT ID: NCT02808871 Completed - Clinical trials for Rheumatoid Arthritis Interstitial Lung Disease

Phase ll Study of Pirfenidone in Patients With RAILD (TRAIL1)

Start date: April 7, 2017
Phase: Phase 2
Study type: Interventional

The purpose of this study is to to assess the safety and tolerability of pirfenidone 2403 mg/day for the treatment of RA-associated interstitial lung disease.

NCT ID: NCT02808819 Completed - Asthma Clinical Trials

A Safety Extension Study With Benralizumab for Asthmatic Adults on Inhaled Corticosteroid Plus Long-acting β2 Agonist

MELTEMI
Start date: June 30, 2016
Phase: Phase 3
Study type: Interventional

The purpose of this study is to continue to characterize the safety profile of benralizumab administration and monitor the pharmacodynamic activity of the drug in those asthma patients who remain on treatment for at least 16 weeks and not more than 40 weeks in the predecessor study D3250C00021 (BORA, NCT02258542).

NCT ID: NCT02808741 Completed - Clinical trials for Invasive Aspergillosis

Evaluation of Immediate Release Tablet

Start date: July 2016
Phase: Phase 1
Study type: Interventional

Single dose comparison of liquid and solid formulation, followed by study of effect of high fat breakfast. Evaluation of multiple dose pharmacokinetics and tolerability

NCT ID: NCT02808442 Completed - Clinical trials for Relapsed B-cell Acute Lymphoblastic Leukemia

Study of UCART19 in Pediatric Patients With Relapsed/Refractory B Acute Lymphoblastic Leukemia

PALL
Start date: June 3, 2016
Phase: Phase 1
Study type: Interventional

This study aims to evaluate the safety and feasibility of UCART19 to induce molecular remission in pediatric patients with relapsed or refractory CD19-positive B-cell acute lymphoblastic leukemia (B-ALL).

NCT ID: NCT02807636 Completed - Clinical trials for Urothelial Carcinoma

Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma

IMvigor130
Start date: June 30, 2016
Phase: Phase 3
Study type: Interventional

A Phase III, randomised study of atezolizumab alone and in combination with chemotherapy versus chemotherapy alone in participants with untreated advanced urothelial cancer.

NCT ID: NCT02807181 Completed - Clinical trials for Intrahepatic Cholangiocarcinoma

SIRT Followed by CIS-GEM Chemotherapy Versus CIS-GEM Chemotherapy Alone as 1st Line Treatment of Patients With Unresectable Intrahepatic Cholangiocarcinoma

SIRCCA
Start date: January 2017
Phase: Phase 2/Phase 3
Study type: Interventional

The study will evaluate the benefit of applying Selective Internal Radiation Therapy (SIRT) using SIR-Spheres Y-90 resin microspheres prior to receiving systemic chemotherapy treatment (cisplatin-gemcitabine, or CIS-GEM) in patients with unresectable intrahepatic cholangiocarcinoma. Half of the patients will be randomized to CIS-GEM chemotherapy plus SIRT, and half of the patients will be randomized to CIS-GEM alone.